Guiheen Lawrence P. has made notable stock transactions involving ADMA Biologics, Inc., which could indicate a positive outlook for the company. On November 16, 2026, he reported acquiring 10,000 shares at a price of $5 each. This acquisition is significant as it reflects Lawrence's confidence in ADMA Biologics and its potential growth in the biological products industry.
ADMA Biologics, Inc. operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company is incorporated in Delaware and has its business address in Ramsey, New Jersey. It trades under the ticker symbol ADMA.
The recent filing reveals that Lawrence acquired 10,000 shares of common stock on the same day he made the report. Following this transaction, he now owns a total of 73,599 shares of ADMA Biologics. The filing also indicates that he disposed of 10,000 shares at a price of $13.92 each, resulting in a significant profit.
This activity may affect various stakeholders, including investors, analysts, and competitors in the biological products market. Lawrence's actions could be interpreted as a signal of confidence in ADMA's future performance, potentially influencing investor sentiment and market dynamics.
Details were not available in the SEC filing regarding future plans or additional transactions. As such, it remains to be seen how this insider activity will impact ADMA Biologics and its standing within the industry.
Read Next
Gilliam Joseph E reports significant stock transactions
ADMA Biologics CEO Grossman Reports Major Stock Transactions
Saba Capital Management reveals stock acquisitions in SEC filing
Evans Bronwyn Reports Multiple Stock Transactions
Halozyme CEO Torley Helen Reports Major Stock Transactions
Saba Capital Management purchases 6,800 shares of JOF





